GSK has revealed it will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST).  Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.   The acquisition includes lead molecule, IDRX-42, a highly selective KIT tyrosine […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!